Table 5.

Ranking probabilities and surface under the cumulative ranking (SUCRA) values of treatments according to different outcomes.

	1st	2nd	3rd	4th	5th	6th	7th	8th	9th	SUCRA
Total cardiovascular disease
Control	0	0	0	0	0.3	5.3	33.2	61.3		0.1
Omega-3	0	0	0	0.2	7.5	43.3	44.3	4.7		0.2
Simvastatin	0	0	0.1	0.8	13.2	45.5	19.6	20.7		0.2
Pravastatin	0.7	11.4	27.2	34.6	25.8	0.3	0	0		0.6
Fluvastatin	85.4	7.1	1.7	1.5	2.1	0.6	0.3	1.3		0.9
Lovastatin	3.6	32.0	30.1	17.5	15.6	1.0	0.2	0.1		0.7
Atorvastatin	0.7	11.3	31.5	37.5	19.0	0	0	0		0.6
Rosuvastatin	9.7	38.3	9.5	7.9	16.5	3.9	2.4	11.9		0.6
Coronary heart disease
Control	0	0	0	0	0	2.5	97.5			0
Omega-3	0	0	0.1	1.2	14.8	83.3	0.7			0.2
Simvastatin	0	26.8	26.1	24.6	18.8	3.4	0.3			0.6
Pravastatin	13.3	31.6	28.0	17.9	8.8	0.4	0			0.7
Lovastatin	3.2	12.3	21.7	29.5	29.1	3.9	0.3			0.5
Atorvastatin	78.1	15.9	4.9	1.2	0	0	0			1
Rosuvastatin	5.4	13.5	19.4	25.6	28.6	6.4	1.2			0.5
Myocardial infarction
Control	0	0	0	0	0.1	1.4	18.8	66.5	13.2	0.1
Omega-3	0	0	0.1	0.8	7.4	33.0	49.5	8.5	0.7	0.3
Simvastatin	1.0	3.7	5.8	10.1	18.0	29.2	17.4	11.6	3.3	0.4
Pravastatin	8.4	30.1	28.2	19.0	10.6	3.3	0.4	0	0	0.7
Fluvastatin	0.2	0.8	0.7	0.9	2.0	3.6	5.4	7.4	78.9	0.1
Lovastatin	13.3	32.8	13.5	12.0	13.4	9.3	3.7	1.8	0.3	0.7
Atorvastatin	2.8	16.0	30.9	30.9	16.5	2.7	0.2	0	0	0.7
Pitavastatin	72.7	6.0	2.9	2.7	3.5	3.0	2.1	4.0	3.6	0.9
Rosuvastatin	2.1	10.6	17.9	23.6	28.5	14.4	2.6	0.3	0	0.6
Stroke
Control	0	0	0.1	1.2	13.3	38.1	37.2	10.1		0.2
Omega-3	0	0	0.4	2.3	8.0	21.7	39.6	28.0		0.2
Simvastatin	10.9	23.4	23.1	19.5	13.0	6.6	2.4	1.1		0.7
Pravastatin	1.9	8.0	16.8	27.3	28.2	14.7	2.2	0.7		0.5
Fluvastatin	42.2	8.2	2.9	2.6	3.4	3.0	6.1	31.5		0.6
Atorvastatin	5.5	18.2	28.3	25.2	16.3	5.6	0.6	0.2		0.6
Pitavastatin	25.9	15.5	4.6	4.7	5.5	5.2	10.6	28.0		0.5
Rosuvastatin	13.5	26.6	23.7	17.1	12.3	5.2	1.2	0.4		0.7